We Think Zymeworks (NASDAQ:ZYME) Can Afford To Drive Business Growth
Yahoo FinanceApr 28 10:26 ET
HER2+ Market to Accelerate Substantially by 2034, Predicts DelveInsight | Key Companies - Zymeworks, Jazz Pharmaceuticals, Ambrx, AnBogen Therapeutics, Enliven Therapeutics, Roche
New York, USA, April 17, 2024 (GLOBE NEWSWIRE) -- HER2+ Market to Accelerate Substantially by 2034, Predicts DelveInsight | Key Companies - Zymeworks, Jazz Pharmaceuticals, Ambrx, AnBogen Therapeutics, Enliven
GlobeNewswireApr 17 13:00 ET
Maintaining Hold on Zymeworks: ZW191's Potential Amidst Competitive and Regulatory Hurdles
TipRanksApr 12 06:27 ET
Zymeworks Announces Upcoming Financial Report
TipRanksApr 11 06:37 ET
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve
GlobeNewswireApr 11 06:00 ET
Zymeworks Unveils Promising Cancer Research
TipRanksApr 8 07:07 ET
Zymeworks Presents New Data From Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced five presentations including new data from its preclinical development-stage programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting being held in San Diego, California April 5-10, 2024.
GlobeNewswireApr 8 06:00 ET
Zymeworks CFO Dr. Astle Exits With Severance Package
TipRanksApr 4 06:13 ET
Zymeworks Shares Sink After Company Removes CFO Christopher Astle
Seeking AlphaApr 1 12:43 ET
Zymeworks Announces Executive Shake-Up, Appoints Interim CFO
TipRanksApr 1 09:12 ET
Zymeworks Inc. Strengthens Board With Dr. Gallagher's Appointment
TipRanksMar 28 16:33 ET
Zymeworks Bolsters Board With Oncology Expert
TipRanksMar 28 06:37 ET
Zymeworks Announces Appointment of Neil Gallagher to Its Board of Directors
Zymeworks Announces Appointment of Neil Gallagher to Its Board of Directors
Dow JonesMar 28 06:00 ET
Zymeworks Engages Investors in April Conferences
TipRanksMar 27 06:37 ET
Zymeworks Announces Participation in Upcoming Investor Conferences
Globe NewswireMar 27 06:00 ET
Analysts' Top Healthcare Picks: Zymeworks (ZYME), 89bio (ETNB)
TipRanksMar 13 10:00 ET
Zymeworks Is Maintained at Overweight by Wells Fargo
Zymeworks Is Maintained at Overweight by Wells Fargo
Dow JonesMar 12 07:27 ET
Express News | Wells Fargo Maintains Overweight on Zymeworks, Raises Price Target to $14
Moomoo 24/7Mar 12 07:17 ET
Buy Rating Affirmed for Zymeworks Amid Positive HERIZON Study Outlook and Robust Commercial Prospects of Zanidatamab
TipRanksMar 12 05:16 ET
Stifel Nicolaus Keeps Their Buy Rating on Zymeworks (ZYME)
TipRanksMar 11 22:05 ET
No Data
No Data